[The optimization of epilepsy therapy with finlepsin].
A clinical pharmacological study (270 patients) was made to optimize therapy of epilepsy with carbamazepines (finlepsin and its retard form). It was established that insufficient (standard) doses of finlepsin are often used, serum levels of the drug are not estimated, drug pharmacokinetics is not taken into account, maximum permissible doses of the drug are not reached. Estimation of the efficiency of both preparations in the treatment of various types of the seizures was carried out. The advantages of finlepsin-retard were demonstrated.